Funded Project Details - FY2021
|Title:|| Development of dihydrocaffeic acid and malvidin- 3 - glucoside for the treatment of depression and anxiety disorders|
|Congressional District Code:
||Biomedical Laboratory R&D
|| October 2019 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Depression, anxiety, and other stress-related disorders are widespread psychological conditions with broad health implications, including negative impacts on cardiovascular and metabolic functions and on mental health, including memory dysfunction. The prevalence of depression is even higher in veterans. It was estimated that approximately 30% of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) veterans are affected by depression. Current available treatments for depression mai...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.